Английская Википедия:AstraZeneca plc v Commission

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox Court Case

AstraZeneca AB and AstraZeneca plc v Commission (2012) C-457/10 P is an EU competition law case, concerning monopoly and abuse of a dominant position.[1]

Facts

AstraZeneca plc misrepresented the dates of invention of a stomach ulcer drug, omeprazole (its brand was Losec), to national patent offices and courts. It also deregistered a capsule version, to get longer patent protection, and thus prevent other companies producing generic versions of the drug.

The Commission fined AstraZeneca €60 million. AstraZeneca brought an action against the Commission to annul the fine.

Judgment

The Court of Justice upheld the Commission's fine of €60 million based on ‘highly misleading representations with the aim of leading public authorities into error’, and depriving generic drug manufacturers of the ability to produce the drug.[2] The fact that AstraZeneca was allowed to withdraw Losec capsules under registration procedures did not mean it was not an abuse to do so under article 102.

Шаблон:Cquote

See also

Notes

Шаблон:Reflist

References

  1. A Jones, B Suffrin and N Dunne, EU Competition law: Text, Cases & Materials (8th edn 2023) ch 7
  2. (2012) C-457/10 P